Verve Therapeutics

About

Verve Therapeutics is a genetic medicines company.

Cambridge,Massachusetts,United States
101 - 250
https://www.vervetx.com/

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $63M
Industries: Biotechnology,Genetics,Life Science
Founded date: Jan 1, 2018
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:VERV
Legal Name: Verve Therapeutics, Inc.

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$482.20M

Verve Therapeutics has raised a total of $482.20M in funding over 2 rounds. Their latest funding was raised on Jun 16, 2021 from a IPO round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 16, 2021	IPO	$266.70M	—	—	—	Detail
Jan 19, 2021	Series B	$94M	12	Casdin Capital Wellington Management	—	Detail
Jun 11, 2020	Series A	$63M	6	GV	—	Detail
May 7, 2019	Series A	$58.50M	4	GV	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

14

Verve Therapeutics is funded by 14 investors. Casdin Capital and Wellington Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
Casdin Capital	Yes	Series B
Wellington Management	Yes	Series B
Biomatics Capital Partners	—	Series B
Cormorant Asset Management	—	Series B
GV	—	Series B
Janus Henderson Investors	—	Series B
Logos Capital	—	Series B
Novo Holdings	—	Series B
RA Capital Management	—	Series B
Redmile Group	—	Series B